🇺🇸 FDA
Patent

US 9689042

Use of glycolytic pathways for inhibiting or measuring oncogenic signaling

granted A61KA61K2039/517

Quick answer

US patent 9689042 (Use of glycolytic pathways for inhibiting or measuring oncogenic signaling) held by The Regents of the University of California expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jun 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/517